- |||||||||| zonisamide / Generic mfg., levetiracetam / Generic mfg., topiramate / Generic mfg.
Journal, Monotherapy: Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy. (Pubmed Central) - Jan 6, 2024
Lamotrigine-levetiracetam duotherapy in first trimester was associated with a 60% lower risk of MCM than valproate monotherapy, while lamotrigine-topiramate was not associated with a reduced risk. Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined.
- |||||||||| levetiracetam / Generic mfg.
Biomarker, Journal: Structural connectivity as a predictive factor for responsiveness to levetiracetam treatment in epilepsy. (Pubmed Central) - Jan 3, 2024
Duotherapy with lamotrigine and levetiracetam may be favored to treat epilepsy in people with childbearing potential compared with valproate regarding MCM, but whether this combination is as effective as valproate remains to be determined. We demonstrated that structural connectivity is a potential predictive factor for responsiveness to LEV treatment in patients with newly diagnosed epilepsy.
- |||||||||| levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: R33: Levetiracetam in Early Psychosis (clinicaltrials.gov) - Jan 3, 2024
P2, N=84, Recruiting,
These preliminary results confirm the reduction of DOAC's PC by I-ASMs and suggest a better manageability of apixaban, dabigatran, and edoxaban independently from the concomitant ASM, whereas rivaroxaban seems the most liable to PC alterations with I-ASMs. Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- |||||||||| levetiracetam / Generic mfg.
Enrollment change, Trial termination: Levetiracetam Treatment of Neonatal Seizures (clinicaltrials.gov) - Dec 29, 2023
P1/2, N=60, Terminated,
Trial completion date: Oct 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Jun 2024 N=100 --> 60 | Recruiting --> Terminated; The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.
- |||||||||| Clinical data, Preclinical, Review, Journal: Caffeine and Its Interactions with Antiseizure Medications-Is There a Correlation between Preclinical and Clinical Data? (Pubmed Central) - Dec 27, 2023
Experimental studies reveal that caffeine (trimethylxanthine) at subconvulsive doses, distinctly reduced the anticonvulsant activity of numerous antiseizure medications (ASMs) in rodents, oxcarbazepine, tiagabine and lamotrigine being the exceptions...ASMs vulnerable to caffeine in experimental models of seizures encompass carbamazepine, phenobarbital, phenytoin, valproate, gabapentin, levetiracetam, pregabalin and topiramate...A question arises why large clinical studies failed to confirm the results of experimental and case-report studies. A possibility exists that the proportion of patients taking ASMs resistant to caffeine may be significant and such patients may be sufficiently protected against the negative activity of caffeine.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Neurodevelopmental Profile of a Pediatric Patient with Catamenial Epilepsy (Shubert Complex (Posters 1-60) / Majestic Complex (Posters 61-120)) - Dec 26, 2023 - Abstract #INSNewYork2024INS_Newyork_1302;
This is especially important in pediatric populations where neuropsychological development is ongoing. Our case study is one of the first to provide information on the neurocognitive profile of a pediatric patient with catamenial epilepsy, but more information and research is necessary.
- |||||||||| levetiracetam / Generic mfg.
Preclinical, Journal: Effect of intranasal and oral administration of levetiracetam on (Pubmed Central) - Dec 25, 2023
Results of immunofluorescence revealed largely the same expression patterns of SV2A in the CA3 area of hippocampus as those in the entire hippocampus. Our study revealed the same antiepileptic and neuronal protective effects by the nasal and oral administrations of LEV, without changing the expression level of SV2A.
- |||||||||| levetiracetam / Generic mfg.
Journal: Obstructive sleep apnea induced bilateral tonic- clonic seizure of unknown origin: A case series of a novel association. (Pubmed Central) - Dec 21, 2023
All 2 patients were seizure-free after being treated with levetiracetam, chronic continuous positive airway pressure therapy in 2, and only continuous positive airway pressure in the other...Although further investigation is required to clarify this association, underlying obstructive sleep apnea should be ruled out in patients with a first-ever bilateral tonic-clonic seizure. Whether or not continuous positive airway pressure alone could effectively treat hypoxia and deranged cortical excitability, which may lead to seizures in cases with longstanding obstructive sleep apnea, is yet to be explored.
- |||||||||| prednisone / Generic mfg., levetiracetam / Generic mfg.
Enrollment closed: CAN-GT: rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (clinicaltrials.gov) - Dec 20, 2023
P1/2, N=24, Active, not recruiting,
Whether or not continuous positive airway pressure alone could effectively treat hypoxia and deranged cortical excitability, which may lead to seizures in cases with longstanding obstructive sleep apnea, is yet to be explored. Enrolling by invitation --> Active, not recruiting
- |||||||||| Review, Journal: Status epilepticus in the ICU. (Pubmed Central) - Dec 20, 2023
Initial management consists of rapid administration of benzodiazepines and one of the following non-sedating intravenous antiseizure medications (ASM): (fos-)phenytoin, levetiracetam, or valproate; other ASM are increasingly used, such as lacosamide or brivaracetam...At this step, management may include non-sedating or sedating compounds including ketamine and barbiturates...Short-term mortality ranges from 10 to 15% after SE and is primarily related to increasing age, underlying etiology, and medical comorbidities. Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE.
- |||||||||| levetiracetam / Generic mfg.
Journal: Rapid Administration of Undiluted Loading Doses of Levetiracetam. (Pubmed Central) - Dec 20, 2023
Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE. Rapid IV administration of undiluted doses of LEV is both safe and tolerable in loading doses of 2500 mg to 4500 mg, allowing for rapid drug administration in the setting of status epilepticus.
- |||||||||| levetiracetam / Generic mfg.
Journal: Efficacy of Levetiracetam as Add-On Therapy in the Treatment of Seizures in Neonates. (Pubmed Central) - Dec 19, 2023
Although the cumulative loading dose of LEV was low and the group of infants studied was heterogeneous, the efficacy of LEV as add-on therapy for the treatment of seizures in neonates was limited. The highest seizure reduction rate was seen after LDC administration.
- |||||||||| NN1213 / Novo Nordisk
Trial completion: SPAR: Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) - Dec 19, 2023
P4, N=79, Completed,
The highest seizure reduction rate was seen after LDC administration. Active, not recruiting --> Completed
- |||||||||| Retrospective data, Journal: Use of Psychotropic Drugs during the COVID-19 pandemic in Minas Gerais, Brazil. (Pubmed Central) - Dec 17, 2023
Active, not recruiting --> Completed The change in the psychotropic drug dispensation profile during the COVID-19 pandemic highlights the need to produce more studies to complete, confirm or rule out this profile and monitor the use of psychotropic drugs by the population in the post-pandemic context.
- |||||||||| levetiracetam / Generic mfg.
Journal: Management of Complications in Neuro-oncology Patients. (Pubmed Central) - Dec 12, 2023
For those with tumor-related epilepsy, monotherapy with a non-enzyme-inducing anticonvulsant is the preferred initial treatment, and levetiracetam remains the preferred first choice...Medical care for patients impacted by primary and secondary central nervous system malignancy is complex and requires a committed team-based approach that routinely calls upon the expertise of physicians across multiple fields. Neurologists have an important role to play and should be familiar with the spectrum of complications impacting these patients as well as the latest recommendations for management.
- |||||||||| Journal: Simple HPLC-UV Method for Therapeutic Drug Monitoring of 12 Antiepileptic Drugs and Their Main Metabolites in Human Plasma. (Pubmed Central) - Dec 9, 2023
It showed to be selective, accurate, precise, and linear over the concentration ranges of 1-50 mg/L for phenobarbital, phenytoin, levetiracetam, rufinamide, zonisamide, and lacosamide; 0.5-50 mg/L for lamotrigine, primidone, carbamazepine and 10-monohydroxycarbazepine; 0.2-10 mg/L for carbamazepine metabolites: 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine and carbamazepine-10,11-epoxide; 0.1-10 mg/L for oxcarbazepine; 2-100 mg/L for felbamate and 3-150 mg/L for ethosuximide. The suitability of the validated method for routine therapeutic drug monitoring was confirmed by quantification of the analytes in plasma samples from patients with epilepsy on combination antiepileptic therapy.
- |||||||||| Review, Journal, Adverse events: Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases. (Pubmed Central) - Dec 8, 2023
We also found published cases of priapism for pregabalin and phenytoin in the literature and FAERS, and at least one reported adverse event of priapism in FAERS for clonazepam, lacosamide, ethosuximide, oxcarbazepine and vigabatrin in which they were considered primary suspect. Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.
- |||||||||| prednisone / Generic mfg., levetiracetam / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: CAN-GT: rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease (clinicaltrials.gov) - Dec 7, 2023
P1/2, N=24, Enrolling by invitation,
Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies. Active, not recruiting --> Enrolling by invitation | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2023 --> Aug 2026
- |||||||||| levetiracetam / Generic mfg.
Journal: Prophylactic removal of a migratory missile from the cerebral ventricles: case report. (Pubmed Central) - Dec 7, 2023
Active, not recruiting --> Enrolling by invitation | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2023 --> Aug 2026 The authors discuss the rationale and technique for removing a nonpowder firearm bullet that has migrated within the cerebral ventricles.
- |||||||||| levetiracetam / Generic mfg.
Biomarker, Journal: Prognostic factors in epilepsy with eyelid myoclonia (Jeavons syndrome). (Pubmed Central) - Dec 5, 2023
Patients with Jeavons syndrome present a high rate of pharmaco-resistance with the need for long-term treatment. Early onset of epilepsy and the presence of intellectual disability appeared to be the most relevant predictors of poor seizure control, suggesting the use of genetic tests to individualize specific etiologies and perhaps adapt the therapeutic strategy.
- |||||||||| Journal: Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry Methods for Antiepileptic Drug Quantitation in Serum. (Pubmed Central) - Dec 5, 2023
TFC-MS/MS testing was performed using a TLX-2 online sample preparation liquid chromatography (SPLC) system coupled to an API 5500 Q-Trap tandem mass spectrometer. Quantification of 10,11-dihydro-10-hydroxycarbamazepine, lacosamide, lamotrigine, levetiracetam, rufinamide, topiramate, and zonisamide was, respectively, performed using calibration curves (2-60
- |||||||||| levetiracetam / Generic mfg.
Journal: Schimmelpenning-Feuerstein-Mims syndrome with benign enlargement of subarachnoid space in infancy. (Pubmed Central) - Dec 5, 2023
Due to the known risk of seizures associated with this condition, the patient was started on levetiracetam and showed adequate compliance. We present this as the first reported case of Schimmelpenning-Feuerstein-Mims syndrome with benign enlargement of the subarachnoid space in an infant presenting with seizures to emphasise the value of collaboration among multidisciplinary professionals to improve the quality of care for such patients.
- |||||||||| Journal: Delineating clinical and developmental outcomes in STXBP1-related disorders. (Pubmed Central) - Dec 4, 2023
Virtual clinical trials using seizure frequency as the primary outcome resulted in wide range of trial success probabilities across the age span, with the highest probability in early childhood between 1 year and 3.5 years. In summary, we delineated epilepsy and developmental trajectories in STXBP1-related disorders using standardized measures, providing a foundation to interpret future therapeutic strategies and inform rational trial design.
- |||||||||| levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Journal, Real-world evidence, Real-world: Real-World Anti-Seizure Medication Treatment Outcomes in Drug-Resistant Focal Epilepsy Patient. (Pubmed Central) - Dec 4, 2023
Overall, reported findings indicated that patient history at baseline and the early selection of an ASM all influenced treatment outcomes. Findings pointed to the complex nature of ASM treatment in drug-resistant focal epilepsy patients calling for additional research to identify the optimal treatment to achieve beneficial patient outcomes.
- |||||||||| levetiracetam / Generic mfg., topiramate / Generic mfg., carbamazepine / Generic mfg.
Journal: Changes over 24 (Pubmed Central) - Dec 4, 2023
Findings pointed to the complex nature of ASM treatment in drug-resistant focal epilepsy patients calling for additional research to identify the optimal treatment to achieve beneficial patient outcomes. The increasing use of newer ASMs in pregnant women has been associated with overall advantages in relation to the frequency and severity of foetal malformation and with advantages in relation to freedom from epileptic seizures.
- |||||||||| clonazepam / Generic mfg., levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Journal: Feasibility of psychological screening in a tertiary epilepsy clinic. (Pubmed Central) - Dec 4, 2023
When taken in small doses, for brief periods as monotherapy, levetiracetam Implementation of simple psychological screening using self-administered questionnaires was feasible in a busy tertiary epilepsy clinic.
|
